Table 2.
Age- and multivariate-adjusted hazard ratios (HRs) for the association between psoriasis and non-fatal CVD *
| Cases † | Person-years | Age-adjusted HR (95% CI) |
Multivariate-adjusted HR ‡ (95% CI) |
|
|---|---|---|---|---|
| Non-fatal CVD | ||||
| No psoriasis | 688 | 1,677,052 | 1.00 | 1.00 |
| Psoriasis | 25 | 32,017 | 1.82 (1.22-2.72) | 1.55 (1.04-2.31) |
| Non-fatal MI | ||||
| No psoriasis | 344 | 1,677,379 | 1.00 | 1.00 |
| Psoriasis | 15 | 32,029 | 2.17 (1.29-3.64) | 1.70 (1.01-2.86) |
| Non-fatal Stroke | ||||
| No psoriasis | 347 | 1,677,377 | 1.00 | 1.00 |
| Psoriasis | 11 | 32,031 | 1.60 (0.88-2.92) | 1.45 (0.80-2.65) |
Specifically MI and stroke.
Four Non-fatal MI cases occurred in participants diagnosed with non-fatal stroke.
Simultaneously adjusted for age, body mass index (underweight <18.5, normal weight 18.5-24.9, overweight 25-29.9, and obesity ≥40 kg/m2), smoking status (never, past, current smoking with 1-14, 15-24 or ≥25 cigarettes/day), alcohol intake (no, <5.0, 5.0-9.9 or ≥10.0 g/d), physical activity (<3.0, 3.0-8.9, 9.0-17.9, 18.0-26.9 or ≥27.0 metabolic equivalent hours/wk), race (Caucasian, Asian, Hispanic or African American), family history of stroke/MI (yes or no), hypertension (yes or no), hypercholesterolemia (yes or no), current aspirin use (yes or no), multi-vitamin use (yes or no), postmenopausal hormone use (premenopause, never, current or past users), oral contraceptives use (never, past or current users).